Our Statement on MOUD

The American College of Obstetricians and Gynecologists (ACOG) makes the following recommendation

• For pregnant women with an opioid use disorder, opioid agonist pharmacotherapy is the recommended therapy and is preferable to medically supervised withdrawal because withdrawal is associated with high relapse rates, which lead to worse outcomes. More research is needed to assess the safety (particularly regarding maternal relapse), efficacy, and long-term outcomes of medically supervised withdrawal.

Generation O supports more research on the use of opioid agonist pharmacotherapy. Our post, Detox During Pregnancy Benefits The Fetus, shows that without relapse, supervised withdrawal is the best option for the fetus. Mothers with Opioid Use Disorder who choose detox during pregnancy should be provided comprehensive support services during pregnancy and after delivery to counteract their chance of relapse.